queried to identify bilateral breast reduction cases. Patients with rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, Raynaud's syndrome, psoriatic arthritis, or scleroderma were identified. Demographic factors, comorbidities, and postoperative complications were compared to patients without CTD using student t-test, chi-square, and risk-adjusted multivariate logistic regression.
CONCLUSION:
Patients with CTD are at significantly increased risk for complications following elective bilateral breast reduction. Such high risk patients require careful patient selection and strategies to minimize risk of serious postoperative complications including venous thromboembolism. 
COMPREHENSIVE 13-YEAR REVIEW OF IMPLANT-BASED BREAST

RESULTS:
A total of 277 patients underwent placement of 466 breast tissue expanders. Although the total overall complication rate was not significantly different between the Alloderm and Total Muscle (TM) groups (31.4% vs. 21.5%, p>0.05), the rate of major complications was significantly higher with Alloderm (26.7% vs. 11.7%, p<.004). The mean initial fill volume was significantly lower in TM compared to Alloderm group (54 ± 47 vs. 167 ± 139, p=0.00003) resulting in a higher number of expansions in patients with total muscle coverage (7.7 vs. 6.1, p=0.00076). However, there was no difference in time to exchange for permanent implant (160.4 vs. 165.8 days, p>0.05). There is also an increased rate of revisions with Alloderm after average follow-up of 55.7 months (10.7% vs. 4.4%, p<0.01). Use of Alloderm added a mean cost of $2,217 for each breast.
CONCLUSION:
Although the use of Alloderm allows increased initial fill volumes and fewer total expansions, this study shows an increased risk of major complications as well as considerable added cost without the touted benefits of decreasing revisions or time to expander exchange. Total muscle coverage remains an excellent option for providing quality breast reconstruction without increased complications.
